GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bausch Health Companies Inc (TSX:BHC) » Definitions » 3-Year ROIIC %

Bausch Health (TSX:BHC) 3-Year ROIIC % : -52.72% (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Bausch Health 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Bausch Health's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -52.72%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Bausch Health's 3-Year ROIIC % or its related term are showing as below:

TSX:BHC's 3-Year ROIIC % is ranked worse than
84.87% of 998 companies
in the Drug Manufacturers industry
Industry Median: 0.915 vs TSX:BHC: -52.72

Bausch Health 3-Year ROIIC % Historical Data

The historical data trend for Bausch Health's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch Health 3-Year ROIIC % Chart

Bausch Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.18 -27.78 -20.98 -16.75 -52.72

Bausch Health Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -52.72 - - -

Competitive Comparison of Bausch Health's 3-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bausch Health's 3-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bausch Health's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Bausch Health's 3-Year ROIIC % falls into.



Bausch Health 3-Year ROIIC % Calculation

Bausch Health's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( 3363.015552 (Dec. 2023) - 982.805229 (Dec. 2020) )/( 32134.003 (Dec. 2023) - 36649.111 (Dec. 2020) )
=2380.210323/-4515.108
=-52.72%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Bausch Health  (TSX:BHC) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Bausch Health 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Bausch Health's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bausch Health Business Description

Traded in Other Exchanges
Address
2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Executives
Seana Lynne Carson Senior Officer
Robert Allen Spurr Senior Officer
Joseph Gordon Senior Officer
Steven Daniel Miller Director
Andrew Charles Von Eschenbach Director
Richard Urbain De Schutter Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Osama Eldessouky Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Amy Wechsler Director
William Douglas Humphries Senior Officer
John Paulson Director
Thomas Ross Sr. Director
Christina Ackermann Senior Officer
Joseph Papa Director, Senior Officer
Paul Herendeen Senior Officer